144 ·Filed May 18, 2026

ARTV

Artiva Biotherapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001736819-26-000003
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

No actionable trading signal. The filing confirms a mechanical tax-withholding-sale, a routine post-vesting event. The insider continues to hold a significant number of restricted shares. Monitor for any future open-market filings (e.g., Rule 10b5-1 plan amendments) that might signal a change in insider sentiment.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
ARTV ▲ +32.16% at T+60d
NEUTRAL call ✓ call won +32.16% · α vs SPY +25.87% · entry $8.55 → $11.30
Entry anchored
May 18, 2026
via day open
T+1d
-8.30%
call -8.30% · α -9.34%
$7.84
settled 5mo ago
T+5d
-10.76%
call -10.76% · α -13.06%
$7.63
settled 4mo ago
T+20d
+16.26%
call +16.26% · α +15.27%
$9.94
settled 4mo ago
T+60d
+32.16%
call +32.16% · α +25.87%
$11.30
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Artiva Biotherapeutics (ARTV) director Christopher Horan filed a Form 144 to sell 7,500 shares (~$69K estimated value) as a sell-to-cover transaction for tax withholding on RSU vesting. This is a routine, non-discretionary sale tied to equity compensation—not a signal of insider bearishness.

Key Facts

  • Form 144 filed by director Christopher Horan for 7,500 common shares.
  • Sale is explicitly described as 'sell-to-cover' for taxes on RSU vesting.
  • Shares were acquired on 5/15/2026 via RSU vesting under issuer's registered plan.
  • Estimated aggregate market value: ~$69,150 (based on recent market price).
  • Proposed sale date: 5/18/2026 — same day as filing.
  • Selling broker: Morgan Stanley Smith Barney LLC.

Financial Impact

Proceeds ~$69K — trivial relative to company's $242M market cap and insider's likely holdings.

dilution

Risk Factors

  • None from this filing itself — the sale is mandated by tax withholding, not discretion.
  • High insider ownership concentration remains a positive governance factor.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001736819-26-000003
Document: 0001736819-26-000003-index.html0001736819-26-000003
Document: 0001736819-26-000003.txt0001736819-26-000003
28 reports for ARTV
Performance horizon
88% Hit rate 14 of 16 directional calls best @ T+20▲ +38.82%Jun 8, 2026
Filters
Rows
Reports for ARTV — sortable, filterable
TypeNow
Sep 11, 2026
20d ago
8-K
NEUTRAL ★ 3/10
$10.14 $8.91▼ −12.13%▼ −11.67%$6.86 (−32.35%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 4/10
$10.79 $10.42▼ −3.43%▼ −2.83%$6.86 (−36.42%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 3/10
$10.79 $10.42▼ −3.43%▼ −2.83%$6.86 (−36.42%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 4/10
$10.79 $10.42▼ −3.43%▼ −2.83%$6.86 (−36.42%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 3/10
$10.79 $10.42▼ −3.43%▼ −2.83%$6.86 (−36.42%)
Sep 9, 2026
23d ago
Insider Cluster
BEARISH ★ 5/10
$10.79 $10.42▲ +3.43%▲ +2.83%$6.86 (+36.42%)
Sep 4, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$11.19 $10.88▼ −2.77%▼ −2.22%$6.86 (−38.70%)
Aug 15, 2026
6w ago
Institutional Cluster
BULLISH ★ 6/10
$11.74 $11.68▼ −0.51%▲ +0.16%$6.86 (−41.57%)
Jul 31, 2026
8w ago
Insider Buy
BULLISH ★ 7/10
$10.76 $11.07▲ +2.88%▲ +1.08%$6.86 (−36.25%)
Jul 28, 2026
9w ago
Insider Buy
BULLISH ★ 6/10
$10.53 $10.02▼ −4.84%▼ −3.30%$6.86 (−34.85%)
Showing 10 of 28

US Market Status

Market Open — Closes in 3h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access